Li Li

发表

CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.

K. Harrington, M. Monga, E. Vokes, 2018, The oncologist.

Dasatinib versus imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: a subanalysis of the DASISION 5-year final report

M. Taniwaki, M. Tanimoto, M. Ogura, 2017, International Journal of Hematology.

Assessing Bioequivalence Using Genomic Data

S. Chow, J. Shao, Li Li, 2004, Journal of biopharmaceutical statistics.

Nivolumab treatment beyond RECIST‐defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial

K. Harrington, E. Vokes, R. Ferris, 2019, Cancer.

Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.

K. Harrington, E. Vokes, R. Ferris, 2018, Oral oncology.

Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use

K. Harrington, E. Vokes, R. Ferris, 2019, Clinical Cancer Research.

1043OTreatment beyond progression with nivolumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the phase 3 checkmate 141 study: A biomarker analysis and updated clinical outcomes

K. Harrington, M. Monga, E. Vokes, 2017 .

Nivolumab versus investigator’s choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age

K. Harrington, R. Ferris, P. Brossart, 2019, Oral oncology.

Treatment-Free Remission (TFR) in Patients with Chronic Phase Chronic Myeloid Leukemia (CML-CP) and in Stable Deep Molecular Response (DMR) to Dasatinib - the Dasfree Study

Martin C. Müller, J. Lipton, R. Paquette, 2016 .

The effect of BMS-582949, a P38 mitogen-activated protein kinase (P38 MAPK) inhibitor on arterial inflammation: a multicenter FDG-PET trial.

Z. Fayad, Joonyoung Kim, W. Hayes, 2015, Atherosclerosis.

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227

L. Urban, K. O'Byrne, S. Ramalingam, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of dose reductions on 5-year efficacy in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) from DASISION.

H. Kantarjian, J. Cortes, E. Jabbour, 2017 .

Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus

M. Pfister, D. Kornhauser, B. Komoroski, 2009, Clinical pharmacology and therapeutics.

ECHO-310: A phase 3, randomized trial of epacadostat + nivolumab + chemo vs EXTREME as first-line treatment of recurrent/metastatic SCCHN.

R. Mehra, J. Bauman, A. Psyrri, 2018 .

First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1

Y. Ohe, M. Nishio, I. Okamoto, 2023, International Journal of Clinical Oncology.